The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by admin
The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.
대표청구항▼
1. A compound of the following formula: or a pharmaceutically acceptable salt or prodrug thereof;wherein:(i) Z1 is —OH or —OR3 and Z2 is —OH, or —OR4, an optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C1-6 heteroalk
1. A compound of the following formula: or a pharmaceutically acceptable salt or prodrug thereof;wherein:(i) Z1 is —OH or —OR3 and Z2 is —OH, or —OR4, an optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C1-6 heteroalkyl, optionally substituted C2-6 heteroalkenyl, optionally substituted C2-6 heteroalkynyl, optionally substituted C6-10 aryl, or optionally substituted 5-10 membered heteroaryl; or (ii) Z1 is —OH or —OR3, and Z2 and wherein the ring is comprised of carbon atoms and optionally one or more additional heteroatoms independently selected from the group consisting of N, S and O taken together form an optionally substituted 5- to 7-membered ring;W3 is CR15;X is a covalent bond, —O—, —N═N—, —C═N—, —NR6—, —C(NR6)—, —S—, —C(O)—, —S(O)—, —S(O)2, or optionally substituted C1-6 alkylene, wherein one, two or three methylene units of the C1-6 alkylene are optionally and independently replaced with one or more groups selected from —O—, —N═N—, —C═N—, —NR6—, C(NR6)—, —S—, —C(O)—, —S(O)—, and —S(O)2—;each instance of R1 is, independently, halogen, —OR8, —CF3, —CN, —NO2, —SO2R8, —SOR8, —C(O)R8, —CO2R8, —C(O)N(R8)2, —CHO, —N3, —N2R8, —N(R8)2, —B(OH)2, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl;each instance of R2 is, independently, —OR9, —N(R9)2, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, or unsubstituted C6-10 aryl;each instance of R3 and R4 is, independently, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C1-6 heteroalkyl, optionally substituted C2-6 heteroalkenyl, optionally substituted C2-6 heteroalkynyl, optionally substituted C6-10 aryl, or optionally substituted 5-10 membered heteroaryl;each instance of R6, R8 and R9 is, independently, hydrogen, —SO2R11, —SOR11, —C(O)R11, —CO2R11, —C(O)N(R11)2, —C(O)NH(R11), —C(O)NH2, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6alkynyl, optionally substituted C1-6 heteroalkyl, optionally substituted C2-6heteroalkenyl, optionally substituted C2-6 heteroalkynyl, optionally substituted C3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-10 aryl, or optionally substituted 5-10 membered heteroaryl;each instance of R11H is, independently, optionally substituted C1-6alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6alkynyl, optionally substituted C1-6 heteroalkyl, optionally substituted C2-6 heteroalkenyl, optionally substituted C2-6 heteroalkynyl, optionally substituted C3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-10 aryl, or optionally substituted 5-10 membered heteroaryl;R15 is hydrogen, halogen, —CF3, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, or optionally substituted C2-6 alkynyl;n is 0, 1, 2 or 3; andwith the proviso that the following compound is excluded: 2. The compound of claim 1, wherein X is a covalent bond, —O—, or —(CH2)—. 3. The compound of claim 1, wherein Z1 and Z2 are both OH. 4. The compound of claim 3, wherein n is 0. 5. The compound of claim 4, wherein R2 is optionally substituted C1-6 alkyl. 6. The compound of claim 5, wherein R2 is C1-6 alkyl substituted with optionally substituted phenyl. 7. The compound of claim 5, wherein R2 is C1-6 alkyl substituted with —CF3 or —CF2CF3. 8. The compound of claim 5, wherein the C1-6 alkyl is substituted with an optionally substituted 5- or 6-membered ring having 0-4 heteroatoms selected from N, O or S. 9. The compound of claim 5, wherein the C1-6 alkyl is substituted with)-N(R0C(O)OR0, wherein each R0 is independently hydrogen or C1-6 alkyl. 10. The compound of claim 4, wherein R2 is unsubstituted C6-10 aryl or optionally substituted 5 to 10 membered heteroaryl. 11. The compound of claim 1, wherein n is 1. 12. The compound of claim 11, wherein R1 is a halogen or —CF3. 13. The compound of claim 11, wherein R2 is unsubstituted C6-10 aryl. 14. The compound of claim 1, which is: or a pharmaceutically acceptable salt or prodrug thereof. 15. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable salt or prodrug thereof. 16. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable salt or prodrug thereof. 17. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable salt or prodrug thereof. 18. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable salt or prodrug thereof. 19. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable salt or prodrug thereof. 20. A compound of the following formula: or a pharmaceutically acceptable salt or prodrug thereof; wherein:X is a covalent bond, —O—, or —(CH2)—;W3 is CH;Z1 and Z2 are both OH;n is 0; andR2 is optionally substituted C1-6 alkyl. 21. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt or prodrug thereof, of claim 1, and a pharmaceutically acceptable excipient, medium, or carrier.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (87)
Barnes Keith D. ; Hu Yulin, 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents.
Bezborodov Vladimir S. (Minsk SUX) Grinkevich Oleg A. (Minsk SUX) Grebenkin Mikhail F. (Moscow SUX) Lapanik Valery I. (Minsk SUX) Minko Anatoly A. (Minsk SUX) Rzhussky Vitaly V. (Minsk SUX) Muravsky , 2-(4,3-Disubstituted phenyl)-5-alkyl-1,3,2-dioxaborinane derivatives and liquid crystal material.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Lou,Rongliang; Zhou,Jiacheng; Bhattacharjee,Ashoke; Chen,Shili; Chen,Yi; Farmer,Jay J.; Goldberg,Joel A.; Hanselmann,Roger; Orbin,Alia; Oyelere,Adegboyega K.; Salvino,Joseph M.; Springer,Dane M.; Tra, Biaryl heterocyclic compounds and methods of making and using the same.
Cavezzan Jacques (Villeurbanne FRX) Priou Christian (Villeurbanne FRX), Cationically crosslinkable polyorganosiloxanes and antiadhesive coatings produced therefrom.
Gray George W. (Cottingham GB3) Hird Michael (Hull GB3) Lacey David (Hull GB3) Toyne Kenneth J. (Hull GB3) Reiffenrath Volker (Rossdorf DEX) Wchtler Andreas (Griesheim DEX) Krause Joachim (Dieburg DE, Fluorinated oligophenyls and their use in liquid crystal materials.
Priou Christian (Villeurbanne FRX), Initators for the cationic crosslinking of polymers containing organofunctional groups, crosslinkable polyorganosiloxane.
Wand,Michael D.; More,Kundalika M.; Thurmes,William N., Liquid crystal compositions comprising an organogermanium compound and methods for using the same.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Benson Bradley J. (Chapel Hill NC) Chen Xiannong (Athens GA) Cianciolo George J. (Chapel Hill NC) Diaz Jose-Luis (Durham NC) Ishaq Khalid S. (Chapel Hill NC) Morris-Natschke Susan L. (Apex NC) Uhing , N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cyto.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Frances, Jean-Marc; Gambut, Lucille, Plastic material surface treatment with a polymerizable and/or crosslinkable organic composition having reactive functions.
Schlosser Hubert (Glashutten/Taunus DEX) Wingen Rainer (Hattersheim/Main DEX) Manero Javier (Frankfurt am Main DEX), Process for cross-coupling aromatic boronic acids with aromatic halogen compounds or perfluoroalkylsulfonates.
Butlin, Margaret Anne; Butlin, Roger John; Hogan, Philip John; Meudt, Andreas, Protected forms of N-(3-methoxy-5-methylpiperazin-2-yl)-2-(4-[1,3,4,-oxadiazol-2-yl]phenyl)-pyridine-3-sulphonamide.
Barker Andrew J. (Macclesfield GB2) Hughes Leslie R. (Macclesfield GB2) Marsham Peter R. (Poynton GB2) Oldfield John (Wilmslow GB2) Pegg Stephen J. (Macclesfield GB2), Quinazoline derivatives possessing anti-tumor activity.
Reiffenrath Volker (Rossdorf) Krause Joachim (Dieburg) Wchtler Andreas (Griesheim) Geelhaar Thomas (Mainz DEX) Coates David (Wimborne GBX) Sage Ian (Broadstone GBX) Greenfield Simon (Poole GBX), Smectic liquid-crystal medium.
Priou Christian ; Soldat Andre,FRX ; Kerr ; III Stuart R. ; Beaty Reeshemah, Stable polyorganosiloxane based compositions with cross-linkable functional groups and their use for producing antiadhesive coating.
Bach Nicholas James ; Draheim Susan Elizabeth ; Dillard Robert Delane ; Mihelich Edward David ; Sawyer Jason Scott ; Beight Douglas Wade ; Phillips Michael LeRoy ; Suarez Tulio ; Sall Daniel Jon ; Ba, Substituted tricyclics.
Fuss Robert Walter,DEX ; Manero Javier,DEX ; Schlosser Hubert,DEX ; Wingen Rainer,DEX, Thiadiazole derivatives, process for their preparation, and their use as precursors for the production of liquid crystal.
Hudson Derek (San Anselmo CA) Johnson Charles R. (Berkeley CA) Ross Michael J. (Hillsborough CA) Shoemaker Kevin R. (San Francisco CA) Cass Robert T. (San Mateo CA) Giebel Lutz B. (Burlingame CA), Thin film HPMP matrix systems and methods for constructing and displaying ligands.
Marie-Christine Cotting FR; Gerard Joubert FR; Olivier Loubet FR, Use of silicone compositions cross-linkable by cationic process under UV radiation and of an onium borate type photoinitiator for coating flat joints, particularly cylinder head gaskets.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.